Monitoring C-Reactive Protein in Biologic Naive Patients With Ulcerative Colitis Undergoing Infliximab Remission Induction Therapy

被引：0
|
作者：
Suzuki, Yasuo
Iwasa, Ryota
Yamada, Akihiro
机构：
来源：
GASTROENTEROLOGY | 2014年 / 146卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Su1122
引用
收藏
页码：S381 / S381
页数：1
相关论文
共 50 条
  • [21] SIGNIFICANCE OF C-REACTIVE PROTEIN IN THE MANAGEMENT OF ULCERATIVE-COLITIS
    SHARMA, MP
    SARIN, S
    MALAVIYA, AN
    KARMARKAR, MG
    INDIAN JOURNAL OF MEDICAL RESEARCH, 1982, 75 (JUN) : 858 - 861
  • [22] Efficacy of Tacrolimus in Patients With Active Ulcerative Colitis Refractory to Corticosteroids After Failure of Infliximab Remission Induction Therapy
    Takeuchi, Ken
    Yamada, Akihiro
    Suzuki, Yasuo
    GASTROENTEROLOGY, 2013, 144 (05) : S206 - S206
  • [23] The Pharmacokinetics of Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis
    Brandse, Johannan F.
    van der Kleij, Desiree
    Wolbink, Gert-Jan
    Rigter, Irma M.
    Baars, Paul A.
    Lowenberg, M.
    Ponsioen, Cyriel
    Jansen, Jeroen M.
    van den Brink, Gijs R.
    Mathot, Ron A.
    D'Haens, Geert R.
    GASTROENTEROLOGY, 2014, 146 (05) : S134 - S134
  • [24] Clinical significance of the C-reactive protein-to-bilirubin ratio in patients with ulcerative colitis
    Huang, Xijing
    Liu, Ya
    Zhou, Zhou
    Pan, Yan
    Zhang, Yinghui
    Gao, Caiping
    He, Chong
    FRONTIERS IN MEDICINE, 2023, 10
  • [25] SERUM OF C-REACTIVE PROTEIN IN PATIENTS WITH ULCERATIVE-COLITIS AND CROHNS-DISEASE
    MORANTE, AJL
    SAEZROYUELA, F
    DELMORAL, LY
    LORENTE, MJL
    GIMENEZ, CYO
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 1993, 83 (01) : 5 - 9
  • [26] Can high-sensitive C-reactive protein be a biomarker for patients with ulcerative colitis?
    Takeuchi, Yoshiaki
    Nozo, Fumihiko
    Arai, Katsuhito
    Imawari, Michio
    GASTROENTEROLOGY, 2006, 130 (04) : A213 - A213
  • [27] Elevated C-reactive Protein Predicts Future Corticosteroid Use in Patients With Ulcerative Colitis
    Dalal, Rahul S.
    Buchner, Anna
    Lichtenstein, Gary R.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S423 - S423
  • [28] Cytomegalovirus Colitis Is Rarely Observed After Initiation of Infliximab, Adalimumab, or Vedolizumab in Biologic-Naive Patients With Ulcerative Colitis
    Dalal, Rahul S.
    McClure, Emma L.
    Pruce, Jordan C.
    Allegretti, Jessica R.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S334 - S335
  • [29] Comparison of long-term outcomes of infliximab and adalimumab in biologic-naive patients with ulcerative colitis
    Durak, M. B.
    Baspinar, B.
    Guven, I. E.
    Kivrakoglu, F.
    Kilic, V.
    Kosar, K.
    Erdogan, C.
    Yuksel, I.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I547 - I547
  • [30] Comparison of long-term outcomes of infliximab and adalimumab in biologic-naive patients with ulcerative colitis
    Durak, M. B.
    Baspinar, B.
    Guven, I. E.
    Kivrakoglu, F.
    Kilic, V.
    Kosar, K.
    Erdogan, C.
    Yuksel, I.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I547 - I547
12345